Safety and immunogenicity of the Ad26.COV2.S COVID-19 vaccine candidate: interim results of a phase 1/2a, double-blind, randomized, placebo-controlled trial

@article{Sadoff2020SafetyAI,
  title={Safety and immunogenicity of the Ad26.COV2.S COVID-19 vaccine candidate: interim results of a phase 1/2a, double-blind, randomized, placebo-controlled trial},
  author={J. Sadoff and M. Le Gars and G. Shukarev and D. Heerwegh and C. Truyers and A. M. de Groot and J. Stoop and S. Tet{\'e} and W. van Damme and I. Leroux-Roels and P.-J. Berghmans and M. Kimmel and P. Van Damme and J. de Hoon and W. Smith and K. Stephenson and D. Barouch and S. De Rosa and K. Cohen and J. McElrath and {\'E}. Cormier and G. Scheper and J. Hendriks and F. Struyf and M. Douoguih and J. Van Hoof and H. Schuitemaker},
  journal={medRxiv},
  year={2020}
}
  • J. Sadoff, M. Le Gars, +24 authors H. Schuitemaker
  • Published 2020
  • Medicine
  • medRxiv
  • BACKGROUND The ongoing coronavirus disease (COVID)-19 pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) might be controlled by an efficacious vaccine. Multiple vaccines are in development, but no efficacious vaccine is currently available. METHODS We designed a multi-center phase 1/2a randomized, double-blinded, placebo-controlled clinical study to assesses the safety, reactogenicity and immunogenicity of Ad26.COV2.S, a non-replicating adenovirus 26 based vector… CONTINUE READING
    6 Citations

    References

    SHOWING 1-10 OF 19 REFERENCES
    An mRNA Vaccine against SARS-CoV-2 — Preliminary Report
    • 228
    • PDF
    A Novel Coronavirus from Patients with Pneumonia in China, 2019
    • 7,211
    • PDF
    A Novel Coronavirus from Patients with Pneumonia in 408
      Ad26-vector based COVID-19 vaccine 423